Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced ...

The average one-year price target for Prothena (NasdaqGS:PRTA) has been revised to $20.74 / share. This is an increase of ...

Prothena ( ($PRTA) ) has provided an update. On December 10, 2025, Paula Cobb announced her resignation from Prothena Corporation plc’s Board of ...

Prothena ( NASDAQ:PRTA ) Full Year 2024 Results Key Financial Results Revenue: US$135.2m (up 48% from FY 2023). Net... Prothena Corp PLC (PRTA) reports robust cash reserves and zero debt, setting the ...

Prothena Corporation plc (NASDAQ:PRTA) released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis on Friday. AL (amyloid light-chain) amyloidosis is ...

DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation ...

The build up of amyloid-beta in the brain has been a prime target of Alzheimer's drug developers, including Biogen with its controversial new drug Aduhelm, which was granted the go-ahead from the FDA ...

Prothena is a protein dysregulation specialist with an intriguing pipeline. The company has out-licensed an ATTR Amyloidosis / cardiomyopathy drug to Novo Nordisk, which could win approval after 2024.

DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation ...

Prothena Corporation plc PRTA and partner Roche RHHBY announced plans to advance their pipeline candidate, prasinezumab, into a phase IIb study in patients with early Parkinson’s disease. Parkinson's ...

The stock price of Prothena Corporation (NASDAQ: PRTA), a biotechnology company focused on treatment of diseases that involve protein misfolding or cell adhesion, has seen a a large 13% drop over the ...